A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer. Precise ...
Tires and degrading garbage shed tiny pieces of plastic into the air, creating a form of air pollution that UC San Francisco ...
Lung cancer was nowhere on her radar. "We're definitely seeing more and more, not only lung cancer, but really all cancers in ...
Lung cancer is one of the most common, most dangerous, and most frequently talked about forms of cancer in the world. Of all ...
Getting a diagnosis of lung cancer can be scary, especially when you don't know what to expect. To help, experts will guide ...
2The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas. 3Department of Genomic Medicine, The University of Texas MD Anderson ...
Filming from his hospital bed, the Swedish actor explained he was undergoing a lung ablation, a minimally invasive procedure that uses heat or cold energy to target and destroy cancer cells ...
Eight years ago, Ms Lee Hong Eng, then 38, battled a persistent cough for three months. Then she developed shortness of breath and an unexplained pain in her right shoulder. An X-ray at a ...
Roche’s TIGIT drug has failed to clear the final hurdle in a late-stage cancer trial in what’s proving to be a mostly disappointing year for … ...
Spranger and her team created mouse models of lung cancer with a number of different and well-defined expression patterns of cancer-associated antigens in order to analyze how each antigen impacts T ...
The phase 3 trial found adding the TIGIT candidate tiragolumab to Roche's approved checkpoint inhibitor had no effect on overall survival (OS) in non-small cell lung cancer ... for $1.5 billion.
On Tuesday, Roche said that much-anticipated results from a Phase 3 trial called SKYSCRAPER-01 showed the drug, tiragolumab, did not help people with advanced or metastatic lung cancer live longer ...